MOTS-c in Kidney Disease: Biomarker Studies Do Not Set a Dose

The Missing Study Is Pharmacokinetic, Not Arithmetic

The legacy page assigned kidney-function categories, dose reductions, laboratory intervals, hydration rules, and stop thresholds. Those numbers were not derived from an administered-human MOTS-c renal study.

FDA's multidisciplinary review team summarized the central gap:

“The nominator did not submit, and FDA did not identify clinical studies that provided pharmacokinetic data for MOTS-c-related BDSs.”

The statement appears in FDA's July 2026 Pharmacy Compounding Advisory Committee briefing under “Pharmacokinetic Data.” It is a regulator's evidence finding, not an endorsement of MOTS-c or a dosing recommendation.

The Renal Claim Audit

The human kidney studies are real. Their exposure variable is the body's own peptide, not an administered product.

What the CKD Studies Found—and Did Not Test

Liu and colleagues studied skeletal-muscle and serum MOTS-c in people with stage 5 chronic kidney disease and reported altered endogenous levels and relationships with muscle features (PMID 31432706; DOI 10.1152/ajprenal.00202.2019).

Bolignano and colleagues later examined circulating MOTS-c as an endogenous biomarker in a hemodialysis cohort (PMID 39111290; DOI 10.1159/000540303).

Neither study administered MOTS-c. Therefore neither could measure:

• absorption or bioavailability;
• distribution volume;
• kidney excretion of a product;
• exposure at different eGFR levels;
• metabolite accumulation;
• removal during a dialysis session;
• a dose-response relationship; or
• adverse events caused by administration.

Endogenous concentration and exogenous disposition are different questions.

What a Renal Dose Recommendation Would Require

FDA's March 2024 renal-impairment pharmacokinetic guidance explains that impaired kidney function can alter a drug's pharmacokinetics and sometimes its pharmacodynamics. The purpose of a dedicated or adequately informative study is to determine whether and how dosing instructions should change.

For MOTS-c, a credible renal claim would need a characterized administered substance, human exposure data, kidney-function strata, timed concentration measurements, a validated assay, safety outcomes, and—where relevant—a dialysis sampling design.

None was identified. An eGFR table without those inputs is decoration, not pharmacology.

Dialysis Status Does Not Answer Dialyzability

A person being on hemodialysis does not show that a substance crosses a particular membrane or is removed at a clinically meaningful rate. Dialyzability depends on factors such as molecular behavior, protein binding, distribution, membrane properties, session conditions, and the identity of the administered material.

The hemodialysis biomarker cohort did not dose MOTS-c before a session and calculate extraction or rebound. Its results therefore cannot support timing a product before or after dialysis.

Safety Uncertainty Has More Than One Layer

FDA found no human exposure data for MOTS-c by any route and raised separate concerns involving aggregation, peptide-related impurities, injection-related immunogenicity, and inconsistent substance identity. Kidney disease does not resolve those product questions.

The overdose-management audit explains why no exposure-response curve supports a toxicity threshold. The geriatric evidence review separates kidney function from chronological age, and the older-adult dosing page shows why a dose adjustment cannot precede a validated starting dose.

The Responsible Bottom Line

Published CKD and hemodialysis biomarker studies do not establish how administered MOTS-c behaves in kidney impairment. No evidence-based eGFR reduction, dialysis timing rule, fluid protocol, laboratory cadence, or stop threshold can be calculated from them.

Medical review of this revision is pending. FDA, investigators, institutions, journals, and study authors do not endorse MOTS-c, HealthRX.com, or this page.